A Boston-based startup is in the process of developing a vaccine that can curb methane emissions that are emitted by livestock.
ArkeaBio, an ag-biotech company, is developing a drug that targets methane-producing microorganisms found in animals’ saliva and digestive tracts. Currently, in the early stages, the drug is expected to take at least 2.5 years before potential market availability.
If successful, this drug could represent progress in addressing a major climate challenge: reducing methane emissions from agriculture.
According to the International Energy Agency, the agricultural sector is the largest source of human-generated methane, surpassing fossil fuels and waste.
“The tools to make a really good run at this haven’t existed until the cost of sequencing and the cost of biotechnology came down substantially over the last five to 10 years,” said Colin South, chief executive officer of ArkeaBio.
He added that the company is seeing “better-than-expected results” in currently underway cattle trials.
Also read: US landfill methane output underestimated by 40%: study
ArkeaBio recently closed a $26.5 million Series A venture financing round, with Breakthrough Energy Ventures as the lead investor.
The funding also included new investment from the Centre for Climate Action Joint Venture Ltd., a public-private partnership owned by the New Zealand government and prominent agribusiness companies.